Enalare therapeutics: an agnostic respiratory stimulant for use as a medical countermeasure to treat respiratory depression

Active Definitive Contract Awarded Last action

Contract number
75A50122C00072
Awardee
Awarding agency
Obligated
$12,209,278

Award facts

Opportunity
Contract value 22% obligated
  • $12,209,278.00 Current, with exercised options
  • $56,576,352.00 Potential, with all options
Completion date 68% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Princeton, NJ, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00006 · The purpose of this modification is to extend CLIN0001/base through december 31, 2026, provide supplemental funding to support the development of… $810,132
Other Administrative Action P00005 · The purpose of this modification is to extend CLIN0001/base through september 30, 2026, at no additional cost to the government, update sections B.2 base… $0
Funding Only Action P00004 · The purpose of this modification is to provide supplemental funding to CLIN0001 to support the development of the agnostic respiratory stimulant ENA-001, update… $4,974,417
Other Administrative Action P00003 · No cost extension for CLIN0001 through january 31, 2026 $0
Other Administrative Action P00002 · Correct error from P00001 $0
Funding Only Action P00001 · Provide supplemental funding for ENA-001 $469,302
Original award $5,955,427

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a $56.6 million cost-plus-fixed-fee definitive contract to Enalare Therapeutics Inc. for development of enalare therapeutics, an agnostic respiratory stimulant for use as a medical countermeasure to treat respiratory depression, on September 22, 2022, with no set-aside applied.

This modification extends the base period through December 31, 2026, and provides supplemental funding to support development of an intramuscular formulation of ENA-001 for FDA submission. Place of performance is Princeton, New Jersey. The ultimate contract completion date is September 30, 2028.

The underlying opportunity, posted as a BARDA Broad Agency Announcement on October 16, 2017, solicited proposals for advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. BARDA anticipated multiple awards ranging from $750,000 to $8 million depending on project scope and technical development milestones leading to FDA approval or licensure.

Quick answers

Who was awarded contract 75A50122C00072?

75A50122C00072 was awarded to Enalare Therapeutics Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 22, 2022.

How much is contract 75A50122C00072 worth?

The government has obligated $12,209,278 on 75A50122C00072. Its potential value, with all options, is $56,576,352.

Was contract 75A50122C00072 competed?

The extent of competition for 75A50122C00072 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login